Clinical Trial Update: OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER [Phase 3]

View source ↗

Summary

Phase 3 trial comparing onabotulinumtoxinA with oral oxybutynin ER for overactive bladder; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)
• Oxybutynin ER (oxybutynin)

Snippet

Sponsor: Christopher Patrick Smith | Conditions: Overactive Bladder | Phase 3 | Status: UNKNOWN